Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Read twice and referred to the Committee on Finance.

• Introduced in Senate Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

• Finance Committee
  Senate

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

• WILLIAMS AND JENSEN, PLLC
  for NOVOCURE INC. · New Hampshire · 3rd Quarter 2026 (July 1 - Sep 30)
• MEDTRONIC, INC.
  for MEDTRONIC INC · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
• AVENUE SOLUTIONS
  for SIEMENS MEDICAL SOLUTIONS USA, INC. · Pennsylvania · 3rd Quarter 2026 (July 1 - Sep 30)
• AVENUE SOLUTIONS
  for EDWARDS LIFESCIENCES LLC · California · 3rd Quarter 2026 (July 1 - Sep 30)
• JOHNSON & JOHNSON SERVICES, INC.
  for JOHNSON & JOHNSON SERVICES INC · New Jersey · 3rd Quarter 2026 (July 1 - Sep 30)
• HEARTFLOW, INC.
  for HEARTFLOW, INC. · California · 3rd Quarter 2026 (July 1 - Sep 30)

Bodies those filers lobbied

• HOUSE OF REPRESENTATIVES
  121 filings
• SENATE
  121 filings
• Health & Human Services, Dept of (HHS)
  58 filings
• Centers For Medicare and Medicaid Services (CMS)
  50 filings
• Commerce, Dept of (DOC)
  34 filings
• Food & Drug Administration (FDA)
  30 filings
• U.S. Trade Representative (USTR)
  27 filings
• White House Office
  25 filings

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.